Accipio Ix™

MaxQ AI® is at the cutting-edge of innovative Medical Diagnostic Artificial Intelligence. We aspire to make a meaningful impact on stroke, head trauma, and traumatic brain injury (TBI) treatment across the world driven by the question “what is the cost of a missed intracranial hemorrhage (ICH)?”. By developing comprehensive artificial intelligence software platforms that are seamlessly and securely integrated across acute healthcare indications, we strive to help empower care providers with solutions to make faster, more accurate decisions. Our first platform of medical devices, ACCIPIO®, which means “to learn” in Latin, uses artificial intelligence for assessment of non-contrast head CT for intracranial hemorrhage (ICH) detection. We envision revolutionizing acute care and treatment with the help of world-class clinical partners and state-of-the-art technology. MaxQ AI is globally influencing the new era of AI-empowered care, one that will provide access to expert-level insights across the diagnosis, prognosis, and therapeutic pathway, to make an important difference in patients’ and physicians’ lives.

Accipio Ix is the first solution of MaxQ AI’s ACCIPIO ICH and Stroke Platform with INSIGHT™ that provides automatic identification/detection, notification, acceleration, and prioritization of suspected ICH. It is FDA Cleared, CE Marked, IMOH Approved, TGA Approved. Accipio Ix integrates into a comprehensive, seamless, and secure workflow to augment acute care teams with deep clinical insight and actionable data in minutes to enable care providers across the world to make rapid and accurate assessments in any location, at any time for acute head trauma, TBI, and stroke symptomatic patient care needs.